The Enteroviruses: An Emerging Infectious Disease? The Real, the Speculative and the Really Speculative

  • Mark J. Abzug
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 609)

The human enteroviruses (EVs), which include the polioviruses, Coxsackie A and B viruses, ECHO viruses, and numbered EVs, produce a well-recognized list of clinical manifestations, ranging from mild febrile illness, respiratory infections, and characteristic exanthematous and enanthematous diseases such as hand-foot-mouth disease and herpangina, to potentially severe illnesses such as myocarditis, encephalitis, and neonatal sepsis (Table 1). The EVs have also been linked to a variety of other conditions, including chronic autoimmune diseases, cardiovascular diseases, and neurologic diseases, although definitive proof of causation is lacking (Table 2) (Palacios and Oberste 2005).


Amniotic Fluid Chronic Fatigue Syndrome Chronic Fatigue Syndrome Patient Acute Flaccid Paralysis Congenital Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ablashi DV. (1994). Summary: viral studies of chronic fatigue syndrome. Clin Infect Dis, 18(Suppl 1):S130–S133.PubMedGoogle Scholar
  2. Abzug MJ. (1995). Perinatal enterovirus infections. In Rotbart HA (ed.), Human Enterovirus Infections. American Society for Microbiology Press, Washington, DC, pp. 221–238.Google Scholar
  3. Archard LC, Bowles NE, Behan PO, Bell EJ, and Doyle D. (1988). Postviral fatigue syndrome: persistence of enterovirus RNA in muscle and elevated creatine kinase. J R Soc Med, 81:326–329.PubMedGoogle Scholar
  4. Barnard DL. (2006). Current status of anti-picornavirus therapies. Curr Pharm Des, 12:1379–1390.PubMedCrossRefGoogle Scholar
  5. Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, and Reece PA. (2004). In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother, 48:1766–1772.PubMedCrossRefGoogle Scholar
  6. Baschat AA, Towbin J, Bowles NE, Harman CR, and Weiner CP. (2003a). Is adenovirus a fetal pathogen? Am J Obstet Gynecol, 189:758–763.PubMedCrossRefGoogle Scholar
  7. Baschat AA, Towbin J, Bowles NE, Harman CR, and Weiner CP. (2003b). Prevalence of viral DNA in amniotic fluid of low-risk pregnancies in the second trimester. J Matern Fetal Neonatal Med, 13:381–384.PubMedCrossRefGoogle Scholar
  8. Bowles NE, Bayston TA, Zhang HY, Doyle D, Lane RJ, Cunningham L, and Archard LC. (1993). Persistence of enterovirus RNA in muscle biopsy samples suggests that some cases of chronic fatigue syndrome result from a previous, inflammatory viral myopathy. J Med, 24:145–160.PubMedGoogle Scholar
  9. Castro CM, Cruz AC, Silva EE, and Gomes ML. (2005). Molecular and seroepidemiologic studies of enterovirus 71 in the state of Para, Brazil. Rev Inst Med Trop Sao Paulo, 47:65–71.PubMedGoogle Scholar
  10. CDC. (2006). Enterovirus surveillance–United States, 2002–2004. MMWR Morb Mortal Wkly Rep, 55:153–156.Google Scholar
  11. Chang L, Hsia S, Huang Y, and Lin T. (2002). Left ventricular dysfunction and treatment of fulminant enterovirus 71 infection. Clin Infect Dis J, 35:1444.CrossRefGoogle Scholar
  12. Chang L, Hsia S, Wu C, Huang Y, Lin K, Fang T, and Lin T. (2004a). Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002. Pediatr Infect Dis J, 23:327–331.PubMedCrossRefGoogle Scholar
  13. Chang L, Tsao K, Hsia S, Shih S, Huang C, Chan W, Hsu K, Fang T, Huang Y, and Lin T. (2004b). Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA, 291:222–227.PubMedCrossRefGoogle Scholar
  14. Chen C, Chang Y, Huang C, Lui C, Lee K, and Huang S. (2001). Acute flaccid paralysis in infants and young children with enterovirus 71 infection: MR imaging findings and clinical correlates. Am J Neuroradiol, 22:200–205.PubMedGoogle Scholar
  15. Chern JH, Shia KS, Hsu TA, Tai CL, Lee CC, Lee YC, Chang CS, Tseng SN, and Shih SR. (2004). Design, synthesis, and structure-activity relationships of pyrazolo[3, 4-d] pyrimidines: a novel class of potent enterovirus inhibitors. Bioorg Med Chem Lett, 14:2519–2525.PubMedCrossRefGoogle Scholar
  16. Chia JKS. (2005). The role of enterovirus in chronic fatigue syndrome. J Clin Pathol, 58:1126–1132.PubMedCrossRefGoogle Scholar
  17. Chia JKS and Chia A. (2003). Diverse etiologies for chronic fatigue syndrome. Clin Infect Dis, 36:671–672.PubMedCrossRefGoogle Scholar
  18. Clements GB, McGarry F, Nairn C, and Galbraith DN. (1995). Detection of enterovirus-specific RNA in serum: the relationship to chronic fatigue. J Med Virol, 45:156–161.PubMedCrossRefGoogle Scholar
  19. Cover J, Popek E, Gomez A, Leos NK, and Rogers BB. (2005). Immunohistochemical and PCR analysis of enterovirus from placentas with chronic villitis and from neonates with neurologic impairment. Paediatric Pathology Society and Society for Pediatric Pathology Joint Meeting, Tours, France, Abstract #52.Google Scholar
  20. Cunningham L, Bowles NE, and Archard LC. (1991). Persistent virus infection of muscle in postviral fatigue syndrome. Br Med Bull, 47:852–871.PubMedGoogle Scholar
  21. Cunningham L, Bowles NE, Lane RJ, Dubowitz V, and Archard LC. (1990). Persistence of enteroviral RNA in chronic fatigue syndrome is associated with the abnormal production of equal amounts of positive and negative strands of enteroviral RNA. J Gen Virol, 71:1399–1402.PubMedCrossRefGoogle Scholar
  22. Douche-Aourik F, Berlier W, Feasson L, Bourlet T, Harrath R, Omar S, Grattard F, Denis C, and Pozzetto B. (2003). Detection of enterovirus in human skeletal muscle from patients with chronic inflammatory muscle disease or fibromyalgia and healthy subjects. J Med Virol, 71:540–547.PubMedCrossRefGoogle Scholar
  23. Euscher E, Davis J, Holzman I, and Nuovo GJ. (2001). Coxsackie virus infection of the placenta associated with neurodevelopmental delays in the newborn. Obstet Gynecol, 98:1019–1026.PubMedCrossRefGoogle Scholar
  24. Fu YC, Chi CS, Chiu YT, Hsu SL, Hwang B, Jan SL, Chen PY, Huang FL, and Chang Y. (2003). Cardiac complications of enterovirus rhombencephalitis. Arch Dis Child, 89:368–373.CrossRefGoogle Scholar
  25. Galbraith DN, Nairn C, and Clements GB. (1997). Evidence for enteroviral persistence in humans. J Gen Virol, 78:307–312.PubMedGoogle Scholar
  26. Genen L, Nuovo GJ, Krilov L, and Davis JM. (2004). Correlation of in situ detection of infectious agents in the placenta with neonatal outcome. J Pediatr, 144:316–320.PubMedCrossRefGoogle Scholar
  27. Gow JW and Behan WM. (1991). Amplification and identification of enteroviral sequences in the postviral fatigue syndrome. Br Med Bull, 47:872–885.PubMedGoogle Scholar
  28. Gow JW, Behan WM, Clements GB, Woodall C, Riding M, and Behan PO. (1991). Enteroviral RNA sequences detected by polymerase chain reaction in muscle of patients with postviral fatigue syndrome. BMJ, 302:692–696.PubMedCrossRefGoogle Scholar
  29. Gow JW, Behan WM, Simpson K, McGarry F, Keir S, and Behan PO. (1994). Studies on enterovirus in patients with chronic fatigue syndrome. Clin Infect Dis, 18 (Suppl 1):S126–S129.PubMedGoogle Scholar
  30. Ho M, Chen E, Hsu K, Twu S, Chen K, Tsai S, Wang J, and Shih S. (1999). An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med, 341:929–935.PubMedCrossRefGoogle Scholar
  31. Hsia S, Wu C, Chang J, Lin T, Chung H, Lin K, Hwang M, Chou M, and Chang L. (2005). Predictors of unfavorable outcomes in enterovirus 71-related cardiopulmonary failure in children. Pediatr Infect Dis J, 24:331–334.PubMedCrossRefGoogle Scholar
  32. Huang C, Liu C, Chang Y, Chen C, Wang S, and Yeh T. (1999). Neurologic complications in children with enterovirus 71 infection. N Engl J Med, 341:936–942.PubMedCrossRefGoogle Scholar
  33. Huang F, Jan S, Chen P, Fu Y, and Chi C. (2002). Left ventricular dysfunction and treatment of fulminant enterovirus 71 infection–reply. Clin Infect Dis, 35:1444–1445.PubMedCrossRefGoogle Scholar
  34. Kao SJ, Yang FL, Hsu YH, and Chen HI. (2004). Mechanism of fulminant pulmonary edema caused by enterovirus 71. Clin Infect Dis, 38:1784–1788.PubMedCrossRefGoogle Scholar
  35. Lane RJM, Soteriou BA, Zhang H, and Archard LC. (2003). Enterovirus related metabolic myopathy: a postviral fatigue. J Neurol Neurosurg Psychiatr, 74:1382–1386.PubMedCrossRefGoogle Scholar
  36. Lin T, Chang L, Hsia S, Huang Y, Chiu C, Hsueh C, Shih S, Liu C, and Wu M. (2002). The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis, 34 (Suppl 2):S52–S57.PubMedCrossRefGoogle Scholar
  37. Lin TY, Hsia SH, Huang YC, Wu CT, and Chang LY. (2003a). Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis, 36:269–274.PubMedCrossRefGoogle Scholar
  38. Lin TY, Twu SJ, Ho MS, Chang LY, and Lee CY. (2003b). Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis, 9:291–293.PubMedGoogle Scholar
  39. Lin KH, Hwang KP, Ke GM, Wang CF, Ke LY, Hsu YT, Tung YC, Chu PY, Chen BH, Chen HL, Kao CL, Wang JR, Eng HL, Wang SY, Hsu LC, and Chen HY. (2006). Evolution of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV71. J Med Virol, 78:254–262.PubMedCrossRefGoogle Scholar
  40. McArdle A, McArdle F, Jackson MJ, Page SF, Fahal I, and Edwards RH. (1996). Investigation by polymerase chain reaction of enteroviral infection in patients with chronic fatigue syndrome. Clin Sci, 90:295–300.PubMedGoogle Scholar
  41. McGarry F, Gow J, and Behan PO. (1994). Enterovirus in the chronic fatigue syndrome. Ann Intern Med, 120:972–973.PubMedGoogle Scholar
  42. McIver CJ, Jacques CFH, Chow SSW, Munro SC, Scott GM, Roberts JA, Craig ME, and Rawlinson WD. (2005). Development of multiplex PCRs for detection of common viral pathogens and agents of congenital infections. J Clin Microbiol, 43:5102–110.PubMedCrossRefGoogle Scholar
  43. McMinn P. (2002). An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev, 26:91–107.PubMedCrossRefGoogle Scholar
  44. McMinn P, Stratov I, Nagarajan L, and Davis S. (2001). Neurological manifestations of entero-virus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis, 32:236–242.PubMedCrossRefGoogle Scholar
  45. Mizuta K, Abiko C, Murata T, Matsuzaki Y, Itagaki T, Sanjoh K, Sakamoto M, Hongo S, Murayama S and Hayasaka K. (2005). Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol, 43:6171–6175.PubMedCrossRefGoogle Scholar
  46. Nairn C, Galbraith DN, and Clements GB. (1995). Comparison of coxsackie B neutralization and enteroviral PCR in chronic fatigue patients. J Med Virol, 46:310–313.PubMedCrossRefGoogle Scholar
  47. Nolan MA, Craig ME, Lahra MM, Rawlinson WD, Prager PC, Williams GD, Bye AM, and Andrews PI. (2003). Survival after pulmonary edema due to enterovirus 71 encephalitis. Neurology, 60:1651–1656.PubMedGoogle Scholar
  48. Nuovo GJ, Cooper LD, and Bartholomew D. (2005). Histologic, infectious, and molecular correlates of idiopathic spontaneous abortion and perinatal mortality. Diagn Mol Pathol, 14:152–158.PubMedCrossRefGoogle Scholar
  49. Palacios G and Oberste MS. (2005). Enteroviruses as agents of emerging infectious diseases. J Neurovirol, 11:424–433.PubMedCrossRefGoogle Scholar
  50. Perez-Velez CM, Robinson CC, Anderson MS, McFarland EJ, Wei Q, Nix WA, Oberste S, and Glode MP. (2004). An outbreak of enterovirus type 71 disease in Colorado, summer 2003. 42nd Annual Meeting of IDSA, Boston, MA, Abstract #990.Google Scholar
  51. Reddy UM, Baschat AA, Zlatnik MG, Towbin JA, Harman CR, and Weiner CP. (2005). Detection of viral deoxyribonucleic acid in amniotic fluid: association with fetal malformation and pregnancy abnormalities. Fetal Diagn Ther, 20:203–207.PubMedCrossRefGoogle Scholar
  52. Sanders SA, Herrero LJ, McPhie K, Chow SS, Craig ME, Dwyer DE, Rawlinson W, and McMinn PC. (2006). Molecular epidemiology of enterovirus 71 over two decades in an Australian urban community. Arch Virol, 151:1003–1013.PubMedCrossRefGoogle Scholar
  53. Satosar A, Ramirez NC, Bartholomew D, Davis J, and Nuovo GJ. (2004). Histologic correlates of viral and bacterial infection of the placenta associated with severe morbidity and mortality in the newborn. Hum Pathol, 35:536–345.PubMedCrossRefGoogle Scholar
  54. Shah VA, Chong CY, Chan KP, Ng W, and Ling AE. (2003). Clinical characteristics of an outbreak of hand, foot, and mouth disease in Singapore. Ann Acad Med Singapore, 32:381–387.PubMedGoogle Scholar
  55. Shekhar K, Lye MS, Norlijah O, Ong F, Looi LM, Khuzaiah R, Marzuki I, Hussein I, Wong SL, Mohan J, Sinniah M, and Abu Bakar S. (2005). Deaths in children during an outbreak of hand, foot, and mouth disease in Peninsular Malaysia–clinical and pathological characteristics. Med J Malaysia, 60:297–304.PubMedGoogle Scholar
  56. Shih S, Tsai M, Tseng S, Wan K, Shia K, Li W, Chern J, Chen G, Lee C, Lee Y, Peng K, and Chao Y. (2004). Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother, 48:3523–3529.PubMedCrossRefGoogle Scholar
  57. Tan EL, Chow VT, Kumarasinghe G, Lin RT, Mackay IM, Sloots TP, and Poh CL. (2006). Specific detection of enterovirus 71 directly from clinical specimens using real-time RT-PCR hybridization probe assay. Mol Cell Probes, 20:135–140.PubMedCrossRefGoogle Scholar
  58. Van den Veyver IB, Ni J, Bowles N, Carpenter Jr RJ, Weiner CP, Yankowitz J, Moise Jr KJ, Henderson J, and Towbin JA. (1998). Detection of intrauterine viral infection using the polymerase chain reaction. Mol Genet Metab, 63:85–95.PubMedCrossRefGoogle Scholar
  59. Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, Yu CK, Su IJ, and Liu CC. (2003). Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis, 188:564–570.PubMedCrossRefGoogle Scholar
  60. Wang SM, Lei HY, Huang MC, Wu JM, Chen CT, Wang JN, Wang JR, and Liu CC. (2005). Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema. Pediatr Pulmonol, 39:219–223.PubMedCrossRefGoogle Scholar
  61. Welch J, Maclaran K, Jordan T, and Simmonds P. (2003). Frequency, viral loads, and serotype identification of enterovirus infections in Scottish blood donors. Transfusion, 43:1060–1066.PubMedCrossRefGoogle Scholar
  62. Wenstrom KD, Andrews WW, Bowles NE, Towbin JA, Hauth JC, and Goldenberg RL. (1998). Intrauterine viral infection at the time of second trimester genetic amniocentesis. Obstet Gynecol, 92:420–424.PubMedCrossRefGoogle Scholar
  63. Wu JM, Wang JN, Tsai YC, Liu CC, Huang CC, Chen YJ, and Yeh TF. (2002). Cardiopulmonary manifestations of fulminant enterovirus 71 infection. Pediatrics, 109:E26.PubMedCrossRefGoogle Scholar
  64. Yousef GE, Bell EJ, Mann GF, Murugesan V, Smith DG, McCartney RA, and Mowbray JF. (1988). Chronic enterovirus infection in patients with postviral fatigue syndrome. Lancet, 1:146–150.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Mark J. Abzug
    • 1
  1. 1.Professor of Pediatrics, Department of Pediatrics (Pediatric Infectious Diseases)University of Colorado School of Medicine and The Children's Hospital, The Children's HospitalDenver

Personalised recommendations